Laurus Labs gets USFDA nod for Visakhapatnam unit

The firm is one of the leading manufacturers of APIs for anti-retroviral (ARV), Hepatitis C, and Oncology

Hyderabad-based Laurus Labs Limited has received the Establishment Inspection Report (EIR) from US Food and Drug Administration (USFDA) for its formulations and active pharmaceutical ingredient (API) manufacturing plant, Unit 2 located in Visakhapatnam. The inspection was completed in May, 2017.

Meanwhile, the German Regulatory Authority has also completed the inspection of Unit 2, while the World Health Organisation(WHO) has completed the inspection of Unit 1 and 3 in May 2017, according to the company.

Laurus is one of the leading manufacturers of APIs for anti-retroviral (ARV), Hepatitis C, and Oncology among other therapeutic areas.